房地产 2026 年 02 月 02 日 恒隆地产 (00101) ——零售快速改善，核心利润稳增、分红表现稳定 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2026 年 02 月 02 日 | | --- | --- | | 收盘价（港币） | 9.24 | | 恒生中国企业指数 | 9080.19 | | 52 周最高/最低（港币） | 9.76/5.58 | | H 股市值（亿港币） | 467.23 | | 流通 H 股（百万股） | 5,056.65 | | 汇率（港币/人民币） | 0.8925 | 上 市 公 司 一年内股价与基准指数对比走势： -4% 46% 96% 02/03 03/03 04/03 05/03 06/03 07/03 08/03 09/03 10/03 11/03 12/03 01/03 HSCEI 恒隆地产 资料来源：Bloomberg 相关研究 - 证券分析师 袁豪 A0230520120001 yuanhao@swsresearch.com 陈鹏 A0230521110002 chenpeng@swsresearch.com 联系人 陈鹏 A023 ...

[Table_Title] 研究报告 Research Report 2 Feb 2026 康哲药业 China Medical System Holdings (867 HK) [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 1 月 30 日，康哲药业子公司德镁医药，获得中国国家药品监督管理局（NMPA）批准磷酸芦可替尼乳膏新药上市许 可申请，用于治疗 12 岁及以上儿童和成人患者伴面部受累的非节段型白癜风。芦可替尼乳膏（Opzelura®）是 Incyte 开发的选择性 JAK1/JAK2 抑制剂芦可替尼制成的一种创新型乳膏。2022 年 12 月，德镁医药与 Incyte 就芦可 替尼乳膏订立许可协议，获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国研发、 注册及商业化产品的独家许可权利，以及生产产品的非独家许可权利。 重磅品种芦可替尼获批上市，未来增长可期 Blockbuster Drug Ruxolitinib Cream Appr ...

Investment Rating - The investment rating for the company is "Buy" and it is maintained [6]. Core Insights - The company has announced its earnings forecast for 2025, expecting revenue between 7.75 billion to 7.85 billion, representing a year-on-year growth of approximately 19.8% to 21.3%. Net profit is projected to be between 443 million to 463 million, indicating a year-on-year increase of about 83.7% to 92.0%. Core operating profit is expected to be between 450 million to 470 million, reflecting a year-on-year growth of approximately 44.8% to 51.2% [2][4]. - As of December 31, 2025, the number of stores is expected to reach 11,566, an increase of 1,416 stores compared to December 31, 2024 [2][4]. - The growth in revenue, net profit, and core operating profit is primarily attributed to the company's ongoing expansion into rural markets and steady growth in other regions. The company has implemented a community central kitchen strategy, enhancing operational efficiency and driving profit margins [5][6]. Summary by Sections Revenue and Profit Forecast - The company forecasts 2025 revenue of 7.75 billion to 7.85 billion, with a year-on-year growth of 19.8% to 21.3%. Net profit is expected to be between 443 million to 463 million, showing a growth of 83.7% to 92.0%. Core operating profit is projected at 450 million to 470 million, reflecting a growth of 44.8% to 51.2% [2][4]. Store Expansion - The total number of stores is anticipated to reach 11,566 by December 31, 2025, marking an increase of 1,416 stores from the previous year [2][4]. Operational Efficiency - The company is expected to improve its core operating profit margin to approximately 5.9% in 2025, an increase of about 1.1 percentage points year-on-year. The gross margin is expected to remain stable, with significant potential for optimizing sales and management expense ratios [5][6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company is expected to accelerate store openings in the fourth quarter of 2025, with a focus on penetrating lower-tier markets, which will enhance revenue and profitability [10][14] - The company has achieved significant improvements in single-store performance, with a monthly average of approximately 64,000, reflecting a year-on-year growth of 8.7% [14] - The core operating profit margin for the company is projected to be 7.7%, a year-on-year increase of 1.2 percentage points, driven by scale effects and operational efficiency [9] Revenue Summary - The company has exceeded its store opening targets, adding 805 new stores in Q4 2025, significantly higher than the 250 and 361 stores added in H1 and Q3 of 2025 respectively [14] - Revenue for Q4 2025 is forecasted to be 2.61 billion, representing a year-on-year increase of 19.9%, while the total revenue for 2025 is expected to reach 7.8 billion, up 20.6% year-on-year [13] Profitability Summary - The company is projected to achieve a net profit of 429 million in 2025, reflecting a substantial year-on-year increase of 86.2% [11] - The earnings per share (EPS) is expected to rise from 0.08 in 2024 to 0.16 in 2025, indicating strong growth potential [15] Financial Forecast - The company is expected to generate total revenues of 7.646 billion, 9.031 billion, and 10.619 billion for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 18.2%, 18.1%, and 17.6% [11] - The projected net profit for 2026 and 2027 is 581 million and 749 million respectively, with year-on-year growth rates of 35.3% and 29.0% [11]

Investment Rating - Investment Rating: Buy (Maintain) [3] Core Views - The company is expected to accelerate store openings in the second half of 2025, with a strong willingness from franchisees to cooperate, particularly in underpenetrated markets [10] - The company achieved a core operating profit margin of 7.7% in Q4 2025, a year-on-year increase of 1.2 percentage points, driven by scale effects and operational efficiency improvements [9] - Revenue for Q4 2025 is projected at 2.61 billion yuan, a year-on-year increase of 19.9%, while the core operating profit is expected to reach 200 million yuan, up 41.8% year-on-year [13] Revenue Summary - The company exceeded its store opening targets, adding 805 new stores in Q4 2025, significantly accelerating compared to previous quarters [14] - The average monthly revenue per store in Q4 2025 is estimated at 64,000 yuan, reflecting an 8.7% year-on-year growth [14] - Total revenue forecasts for 2025-2027 are 7.646 billion, 9.031 billion, and 10.619 billion yuan, representing year-on-year growth rates of 18.2%, 18.1%, and 17.6% respectively [11] Profitability Summary - The company is expected to achieve net profits of 429 million, 581 million, and 749 million yuan for 2025-2027, with year-on-year growth rates of 86.2%, 35.3%, and 29.0% respectively [11] - The projected price-to-earnings (P/E) ratios for the next three years are 24, 18, and 14 times [11] Financial Indicators - Key financial indicators for 2025 include a return on equity (ROE) of 12.72% and earnings per share (EPS) of 0.16 yuan [15] - The company’s gross margin is expected to remain stable around 21.79% to 21.93% over the forecast period [16]

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a potential stock price increase of 5% to 15% over the next six months [5]. Core Insights - The company reported a revenue of 2.312 billion yuan for the first half of FY2026, representing a year-on-year growth of 5.7%, and achieved a net profit of 239 million yuan, marking a turnaround from losses [1]. - The growth in Gross Merchandise Volume (GMV) is driven by self-operated products, which accounted for 52.8% of total GMV, up from 43.8% in FY2025. The total GMV for FY2026H1 was 4.1 billion yuan, a decrease of 15% [2]. - The company has expanded its product categories to 801 SKUs, including new categories like seafood and health supplements, enhancing consumer choices and driving sales [2]. - Profitability has significantly improved, with gross margin increasing from 33.6% to 36.4%, attributed to supply chain expansion and category growth. The net profit margin for FY2026H1 was 10.34% [2]. Membership Growth and Brand Recognition - The company has seen a continuous increase in paid membership, reaching 240,000, with its app contributing 18.5% to total GMV. The self-operated GMV through the app remained stable at 28.6% [3]. - The company is expanding its sales channels across multiple platforms, with plans to open its first offline experience store in Beijing in 2026, which is expected to enhance brand influence [3]. Financial Projections - The company forecasts adjusted net profits of 497 million yuan, 540 million yuan, and 590 million yuan for FY2026, FY2027, and FY2028, respectively [3]. - Revenue projections for the upcoming years are as follows: 4.828 billion yuan in FY2026, 5.254 billion yuan in FY2027, and 5.633 billion yuan in FY2028, reflecting growth rates of 9.92%, 8.84%, and 7.21% respectively [4].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage in the market [5][9][47]. Core Insights - The company, known as a leader in the spicy snack sector, has successfully capitalized on the industrialization of snacks and has redefined standards and consumer perceptions in the spicy strip market. The company benefits from a strong brand and channel power, ensuring its competitive edge [5][6][11]. - The domestic spicy snack market is growing rapidly, with significant potential in the konjac market. The company has established a strong presence in both spicy strips and konjac snacks, leveraging its first-mover advantage and comprehensive advantages in product categories, branding, and distribution channels [6][25][39]. - The company is expected to maintain high profitability driven by its konjac product line, with projected net profits for 2025-2027 of 1.384 billion, 1.696 billion, and 2.012 billion RMB, respectively, reflecting growth rates of 29.53%, 22.52%, and 18.65% [7][46]. Summary by Sections Market Performance - As of January 30, 2026, the closing price of the company's stock is 12.29 HKD, with a market capitalization of approximately 29.88 billion HKD [3]. Financial Projections - The company is projected to achieve revenues of 73.73 billion, 86.51 billion, and 99.69 billion RMB for the years 2025-2027, with year-on-year growth rates of 18%, 17%, and 15% respectively [9][46]. - The konjac product line is expected to see revenue growth rates of 38%, 26%, and 21% during the same period, indicating strong market demand [10][46]. Competitive Landscape - The spicy snack market in China is characterized by a high concentration of brands, with the company holding a significant market share of 28% in the spicy strip segment, far ahead of competitors [25][35]. - The company has a robust distribution network, covering approximately 690,000 retail outlets across China, and is actively exploring international markets, including North America and Southeast Asia [40][39]. Growth Drivers - The company is focusing on product innovation and expanding its product offerings, including new flavors and overseas market penetration, which are expected to drive future growth [40][11]. - The report highlights the company's strategic initiatives to enhance its brand positioning and operational efficiency, which are anticipated to sustain its competitive advantage in the market [39][40].

Investment Rating - The report assigns a "Buy" rating for Yum China (09987.HK) [6] Core Insights - The Western fast food industry is expected to expand significantly, with a market size projected to exceed 300 billion yuan by 2025, reflecting a year-on-year growth of 10.3% [1] - Yum China holds a leading market share of 27.5% in the fast food sector, with a high concentration of market power among top brands [1][27] - The company has a strong local innovation capability and a mature supply chain, supporting healthy profitability across its stores [2][29] - The expansion into lower-tier markets is accelerating, with new store formats like KFC Mini and Pizza Hut WOW being introduced [3][29] Summary by Sections 1. Industry Expansion and Market Concentration - The Western fast food market is projected to grow at a compound annual growth rate (CAGR) of 8% from 2020 to 2025, with fast food leading the growth among various segments [21] - The market concentration is increasing, with the top five brands expected to account for 44% of the market share by 2024 [27] 2. Brand Stability and Shareholder Returns - As of Q3 2025, Yum China operates 17,514 stores, with a CAGR of 9% from 2014 to 2024 [2] - The company reported a free cash flow of $1.517 billion in 2024, achieving a shareholder return rate of 166.49% [2] - The membership base reached 575 million, contributing to 57% of sales, indicating strong customer loyalty [2] 3. Accelerated Expansion in Lower-Tier Markets - The introduction of smaller store formats is aimed at penetrating lower-tier cities, with franchise models becoming a core growth engine [3] - The overall restaurant profit margin was reported at 17.3% as of Q3 2025, with continuous improvement in cost control [3] 4. Investment Recommendations - The report anticipates revenues of $11.7 billion, $12.4 billion, and $13.1 billion for 2025, 2026, and 2027 respectively, with net profits of $925 million, $1 billion, and $1.08 billion [4][17] - The current price corresponds to a price-to-earnings (P/E) ratio of 19, 18, and 16 for the years 2025, 2026, and 2027 respectively, reflecting a strong growth outlook [17]

2026 年 2 月 2 日 公司研究 因内码调整进度偏慢拖累，预计 25H2 业绩承压 ——澳优（1717.HK）2025 年业绩前瞻 资料来源：Wind，光大证券研究所预测，股价时间为 2026-01-30 （注：汇率为 1 港币=0.8926 元人民币，23-27 年股本 数分别为 17.80/17.80/17.78/17.78/17.78 亿股） 要点 2025 年业绩前瞻：1）我们预计公司 25 年收入同比增长 1.1%，收入增速较 25H1 放缓主要受国内奶粉业务拖累。2）我们预计公司 25 年归母净利润同比基本持 平；25H2 利润同比下滑主要系内码调整进度低于预期，以及行业竞争加剧，导 致高毛利率的国内奶粉业务收入占比下降。 内部调整滞后、外部行业环境恶化等因素影响，25 年业绩预计不及预期。 1）内码切换进度滞后：25 年 4 月公司启动内码切换工作并同步涨价，消费者提 前囤货，使得内码切换完成时间从三季度延迟至四季度，打乱了下半年核心业务 的增长节奏。2）行业竞争加剧：25 年行业内多家企业推出补贴或降价策略，而 公司此时处于涨价阶段，在价格竞争中处于被动地位。3）行业收入增速下滑： 25 ...

2026 年 02 月 02 日 公司研究 评级：买入(首次覆盖) 研究所： 证券分析师： 曹泽运 S0350525110001 证券分析师： 万鹏辉 S0350524050003 caozy@ghzq.com.cn wanph@ghzq.com.cn [Table_Title] 与齐鲁制药达成合作，持续验证 AI 制药能力 ——英矽智能（03696）点评报告 最近一年走势 事件: 2026 年 1 月 27 日，英矽智能发布公告：公司与齐鲁制药签署战略合作 协议，双方将围绕心血管与代谢类疾病领域，利用英矽智能的 Pharma.AI 平台进行小分子抑制剂的研发。协议总金额超过 9.31 亿港元，包含开发 和销售里程碑付款，以及单位数的后续净销售额分成。 投资要点: | 相对恒生指数表现 | | 2026/01/30 | | | --- | --- | --- | --- | | 表现 | 1M | 3M 12M | | | 英矽智能 | 109.8% | - | - | | 恒生指数 | 5.9% | - | - | | 市场数据 | | 2026/01/30 | | | 当前价格（元） | | 62.90 ...